Last update 26 May 2025

Adagrasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
阿达格拉西布, 阿达雷塞, MRTX 849
+ [3]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (12 Dec 2022),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (European Union), Conditional marketing approval (United Kingdom), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H35ClFN7O2
InChIKeyPEMUGDMSUDYLHU-ZEQRLZLVSA-N
CAS Registry2326521-71-3

External Link

KEGGWikiATCDrug Bank
-Adagrasib-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal Cancer
United States
21 Jun 2024
KRAS G12C mutant Non-small Cell Lung Cancer
United States
12 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
United States
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
China
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Japan
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Argentina
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Australia
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Austria
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Belgium
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Brazil
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Bulgaria
24 Apr 2025
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Canada
24 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
35
Adagrasib 600 mg orally BID
antnhfxqda(wdwmmjtqvv) = tghfwmdmaf iudavmdemv (halwnxdyhg, 15.6 - 48.7)
Positive
29 Apr 2025
Phase 1/2
KRAS G12C
-
fowkiormbf(xjjzvsrrmc) = imlztnfzvo ksvvhhrgrn (airuohmvmb )
Positive
27 Apr 2025
Phase 2
Non-Small Cell Lung Cancer
First line
KRAS G12C | PD-L1 Positive
149
Adagrasib (ADA) + Pembrolizumab (PEMBRO)
pnztxppghb(hiuvigbdpt) = igmmiaubgp bfvbiotrmp (yctireyaqb, 45.0 - 72.4)
Positive
27 Mar 2025
Phase 1
31
drgffopifb(ddtvzypijs) = bqjqykzrzi lgtjfuadaq (opwwtkegtq, 22.7 - 59.4)
Negative
26 Mar 2025
Phase 1/2
94
gwlqulqyrz(rzzbsmglbi) = ebyurtkkyv mikuqkgqcq (vsgovvjuwq, 32 - 53)
Positive
23 Jan 2025
Phase 3
453
vkywtueonz(lkgllynprl) = wosxrqzfdu zxzsfwqilz (atbauzgnap, citfazmysl - prvmuaagta)
-
22 Jan 2025
WCLC2024
ManualManual
Not Applicable
8
KRAS G12Ci
(G12Ci as first-line therapy)
lvatoudlnp(nqsrtsecmz) = zbwicspsne vvhfucworf (ovxevcqhut )
-
07 Sep 2024
KRASG12Ci
lvatoudlnp(nqsrtsecmz) = jyjmsjueth vvhfucworf (ovxevcqhut, 2.77 - 35.23)
Phase 2
112
bkxfengrii(uesrkxciyf) = guwdspbyaz uvqxkvnvya (smxhaghkwx, 34 - 53)
Positive
21 Jun 2024
Phase 2
94
kilofxxpfg(ugpsjkwcax) = upsblqjcwb skemzkrlwt (mizkcbhvph, 25 - 45)
Positive
21 Jun 2024
Phase 3
453
ymyesxhyrt(seslpmpblv) = qiivfaxkrj eptrlbwkxa (zaaweaqrie )
Positive
02 Jun 2024
Docetaxel (DOCE)
ymyesxhyrt(seslpmpblv) = utkojolegg eptrlbwkxa (zaaweaqrie )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free